Atopic dermatitis affects approximately 26 million adults and children in the U.S. WESTLAKE VILLAGE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early ...
WESTLAKE VILLAGE, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful ...
A total of 683 adults and children, age 6 years and older, have been enrolled in the INTEGUMENT-2 trial Topline data from both INTEGUMENT-1 and -2 trials expected by end of 2022 Atopic dermatitis ...
Arcutis Biotherapeutics (ARQT) announced the enrollment of the last subject in the INTEGUMENT-INFANT Phase 2 open-label clinical study, which is evaluating the safety and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback